Payment overview · 2025
General Payments
$90.69
5 reported records · 3 companies
Healthcare provider profile · identity verified
Athar A. Shaikh, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NOGALES, AZ · NPI 1477531713
Verified facts
What the public records show
CMS Open Payments records show Athar A. Shaikh, MD received $90.69 in general payments during 2025 across 5 reported records.
AstraZeneca Pharmaceuticals LP accounted for 61.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.98 | 61.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.07 | 21.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.64 | 17.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $90.69 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1012 | 317 |
| Atorvastatin Calcium | Atorvastatin Calcium | 991 | 290 |
| Losartan Potassium | Losartan Potassium | 805 | 236 |
| Lisinopril | Lisinopril | 669 | 209 |
| Metformin Hcl | Metformin Hcl | 667 | 208 |
| Levothyroxine Sodium | Levothyroxine Sodium | 550 | 144 |
| Carvedilol | Carvedilol | 497 | 153 |
| Alprazolam | Alprazolam | 428 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 419 | 134 |
| Omeprazole | Omeprazole | 391 | 132 |
| Furosemide | Furosemide | 363 | 119 |
| Hydrochlorothiazide | Hydrochlorothiazide | 362 | 116 |
| Finasteride | Finasteride | 315 | 100 |
| Gabapentin | Gabapentin | 304 | 95 |
| Pravastatin Sodium | Pravastatin Sodium | 253 | 81 |
| Doxazosin Mesylate | Doxazosin Mesylate | 240 | 93 |
| Simvastatin | Simvastatin | 213 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 194 | 58 |
| Alendronate Sodium | Alendronate Sodium | 190 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 181 | 54 |
| Trulicity | Dulaglutide | 170 | 36 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 166 | 58 |
| Spironolactone | Spironolactone | 165 | 46 |
| Tramadol Hcl | Tramadol Hcl | 158 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 142 | 44 |
| Allopurinol | Allopurinol | 138 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 134 | 42 |
| Eliquis | Apixaban | 111 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 108 | 28 |
| Glipizide | Glipizide | 102 | 23 |
| Montelukast Sodium | Montelukast Sodium | 102 | 31 |
| Trazodone Hcl | Trazodone Hcl | 102 | 29 |
| Mounjaro | Tirzepatide | 99 | 22 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 95 | 14 |
| Glimepiride | Glimepiride | 93 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 91 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 91 | 27 |
| Famotidine | Famotidine | 90 | 40 |
| Atenolol | Atenolol | 89 | 22 |
| Meclizine Hcl | Meclizine Hcl | 87 | 44 |
| Amoxicillin | Amoxicillin | 86 | 65 |
| Buspirone Hcl | Buspirone Hcl | 84 | 24 |
| Jardiance | Empagliflozin | 80 | 24 |
| Warfarin Sodium | Warfarin Sodium | 78 | 14 |
| Ozempic | Semaglutide | 76 | 14 |
| Sertraline Hcl | Sertraline Hcl | 74 | 28 |
| Irbesartan | Irbesartan | 71 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 70 | 48 |
| Clonidine Hcl | Clonidine Hcl | 65 | 21 |
| Terazosin Hcl | Terazosin Hcl | 65 | 20 |
| Donepezil Hcl | Donepezil Hcl | 64 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 64 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 18 |
| Acarbose | Acarbose | 61 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 28 |
| Valsartan | Valsartan | 53 | 13 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Ezetimibe | Ezetimibe | 49 | 16 |
| Ibuprofen | Ibuprofen | 48 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 12 |
| Mirtazapine | Mirtazapine | 44 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 20 |
| Methotrexate | Methotrexate Sodium | 40 | suppressed |
| Lorazepam | Lorazepam | 37 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | 14 |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Potassium Chloride | Potassium Chloride | 34 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 32 | 13 |
| Dutasteride | Dutasteride | 32 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 13 |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | 14 |
| Celecoxib | Celecoxib | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 24 |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 19 |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Naproxen | Naproxen | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 13 | 12 |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $90.69 · 5 records | AstraZeneca Pharmaceuticals LP | BREZTRI, Kerendia, Ozempic | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error